Home Breaking news To follow today … GUERBET – Capital.fr

To follow today … GUERBET – Capital.fr


Published on

To follow today ... GUERBET

(AOF) – Guerbet announces the approval of a new indication for Lipiodol Ultra-Fluid in Denmark for the chemoembolization (cTACE) of tumors in adults with mid-stage hepatocellular carcinoma. Hepatocellular carcinoma is the primary tumor of the most common liver cancer and is the fourth leading cause of cancer-related death in the world each year.

Lipiodol Ultra-Fluid is used in the cTACE, a minimally invasive procedure that consists of mixing Lipiodol Ultra-Fluid with an anti-cancer agent and injecting this mixture into the liver via the trans-arterial route as targeted locoregional chemotherapy for non-hepatic tumors. resectable. Lipiodol Ultra-Fluid acts as both a contrast medium, a vehicle, an anti-cancer drug eluent and a transient vascular embolization agent.

The approval obtained in Denmark demonstrates Guerbet's commitment to invest in innovating and improving the effectiveness of minimally invasive techniques in oncology.


Pharmacy – Health

In 2018, mergers and acquisitions in the sector were close to $ 200 billion, a significant increase over 2017. And 2019 begins strongly with the recovery by Bristol-Myers Squibb (BMS) of biotech specialist Celgene of oncology, for 74 billion dollars. Together, they give birth to a giant with $ 33.3 billion in sales, the world leader in oncology (62% of its turnover) and in cardiovascular diseases.

Acquisitions are multiplying in biotechnology in response to the need of "Big Pharma" to renew their products. More than 71% of drugs in clinical development last year are from biotech, according to the American trade union, BIO. The Japanese Takeda has acquired the Irish Shire, for 81.7 billion dollars. For its part, Eli Lilly bought the biotech Loxo Oncology for $ 8 billion, just after GSK got hold of another American biotech, Tesaro.


The AOF information reproduced on Capital.fr is extracted from the AOF information service.
This information is protected by intellectual property rights held by OPTION FINANCE SAS, publisher of the real-time trading information service AOF, and its contributors.
Therefore, any reproduction, copy, duplication, modification, transfer, rebroadcasting, translation, commercial exploitation or not, creation of hypertext link or reuse in any way whatsoever of this information are subject to the prior written agreement of OPTION FINANCE SAS and its contributors.
AOF can be reached at the following address [email protected]
OPTION FINANCE SAS collects its data from the sources it considers the safest. However, subject to its gross negligence, OPTION FINANCES SAS and its contributors do not guarantee the absence of error and defects, even hidden, or the completeness or lack of conformity to any use of these data and OPTION FINANCE SAS or one of its contributors, and can not be held responsible for delays or interruptions that could affect access to them.
The user of the OPTION FINANCE SAS service will use the AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.

Source link



Please enter your comment!
Please enter your name here